Medication info

Y2S Omeprazole Magnesium Trihydrate 20mg

Prescription medicationTabletOral · Intravenous injection
Ingredient · strength
Esomeprazole Magnesium Trihydrate›22.25mg / 1 tablet
Manufacturer / importer
Seongyi Bio Pharmaceutical Co., Ltd.
Appearance
Pale pink round film-coated tablet
Packaging
28 tablets/box [14 tablets/PTP x 2]
Approval status
Active

MFDS item code 202106815 · Approved 2021.10.07

Summary

Main use
Treatment and prevention of reflux and gastrointestinal symptoms, ulcers (eradication therapy, rebleeding, etc.), and Zollinger-Ellison syndrome
Who uses it
Adults · Children
Adult dosage
This medicine should be swallowed with a liquid such as water and must not be chewed or crushed. 1. Adults 1) Gastroesophageal reflux disease (GERD) - Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. For patients whose esophagitis has not healed or whose symptoms persist, continue treatment for an additional 4 weeks. - Long-term maintenance therapy to prevent relapse in patients with esophagitis: 20 mg once daily - Symptomatic treatment of gastroesophageal reflux disease without esophagitis: · 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is necessary. · Once symptoms have resolved, subsequent recurrent symptoms may be controlled with 20 mg once daily. · In adults, 20 mg may be taken once daily as needed. As-needed use to control recurrent symptoms is not recommended for patients at high risk of gastric and duodenal ulcers due to nonsteroidal anti-inflammatory drug use. 2) Antibiotic combination therapy for eradication of Helicobacter pylori Administer this medicine 20 mg with amoxicillin 1 g and clarithromycin 500 mg twice daily for 7 days. 3) Short-term treatment of upper gastrointestinal symptoms (pain, discomfort, heartburn) associated with nonsteroidal anti-inflammatory drug use (nonselective or selective COX-2 inhibitors) - 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is necessary. Clinical studies lasting more than 4 weeks have not been conducted. 4) Patients requiring continuous nonsteroidal anti-inflammatory drug treatment - Treatment of gastric ulcers associated with nonsteroidal anti-inflammatory drug use: 20 mg once daily. The treatment period is 4∼8 weeks. - Prevention of gastric and duodenal ulcers associated with nonsteroidal anti-inflammatory drug use: 20 mg once daily. 5) Treatment of Zollinger-Ellison syndrome The recommended initial dose is 40 mg twice daily. Subsequent doses should be adjusted for each patient, and treatment should continue while clinical symptoms are present. Clinical data indicate that most patients can be controlled with doses of 80 ∼ 160 mg per day. Doses greater than 80 mg per day should be divided into two doses. 6) Maintenance therapy following induction of prevention of rebleeding from gastric or duodenal ulcers by intravenous injection Administer 40 mg once daily for 4 weeks following induction of prevention of rebleeding from gastric or duodenal ulcers by intravenous injection. 4. Renal impairment No dose adjustment is necessary. Use with caution because there is limited experience with administration to patients with severe renal impairment. 5. Hepatic impairment No dose adjustment is necessary in patients with mild to moderate hepatic impairment. The dose of this medicine must not exceed 20 mg in patients with severe hepatic impairment. 6. Elderly patients No dose adjustment is necessary.
Children's dosage
Adolescents aged 12 years and older 1) Gastroesophageal reflux disease (GERD) - Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. For patients whose esophagitis has not healed or whose symptoms persist, continue treatment for an additional 4 weeks. - Symptomatic treatment of gastroesophageal reflux disease without esophagitis: · 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is necessary. · Once symptoms have resolved, subsequent recurrent symptoms may be controlled with 20 mg once daily. · In adults, 20 mg may be taken once daily as needed. As-needed use to control recurrent symptoms is not recommended for patients at high risk of gastric and duodenal ulcers due to nonsteroidal anti-inflammatory drug use. Children under 12 years There is no experience with administration of this medicine to children under 12 years.

Ingredients

Manufacturer
Seongyi Bio Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment and prevention of reflux and gastrointestinal symptoms, ulcers (eradication therapy, rebleeding, etc.), and Zollinger-Ellison syndrome

  • Gastroesophageal reflux disease
  • erosive esophagitis
  • esophagitis
  • duodenal ulcer
  • peptic ulcer
  • upper gastrointestinal symptoms
  • pain
  • discomfort
  • burning sensation
  • gastric ulcer
  • duodenal ulcer
  • Zollinger-Ellison syndrome
View approved original text

This medication is used for treating gastroesophageal reflux disease, especially erosive esophagitis, and for long-term maintenance therapy to prevent recurrence in esophagitis patients. It is also used in combination with antibiotics for the eradication of Helicobacter pylori, helping to prevent recurrence in patients with duodenal and peptic ulcers. It is effective in short-term treatment for upper gastrointestinal symptoms due to nonsteroidal anti-inflammatory drugs, as well as for treating and preventing gastric ulcers in patients requiring continuous nonsteroidal anti-inflammatory drug administration. It is also used to treat Zollinger-Ellison syndrome and for maintenance therapy to prevent rebleeding from gastric or duodenal ulcers. This medication is widely utilized for various gastrointestinal diseases and ulcer treatments, assisting in symptom improvement for patients.

Dosage and Administration

Adult dosage

This medicine should be swallowed with a liquid such as water and must not be chewed or crushed. 1. Adults 1) Gastroesophageal reflux disease (GERD) - Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. For patients whose esophagitis has not healed or whose symptoms persist, continue treatment for an additional 4 weeks. - Long-term maintenance therapy to prevent relapse in patients with esophagitis: 20 mg once daily - Symptomatic treatment of gastroesophageal reflux disease without esophagitis: · 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is necessary. · Once symptoms have resolved, subsequent recurrent symptoms may be controlled with 20 mg once daily. · In adults, 20 mg may be taken once daily as needed. As-needed use to control recurrent symptoms is not recommended for patients at high risk of gastric and duodenal ulcers due to nonsteroidal anti-inflammatory drug use. 2) Antibiotic combination therapy for eradication of Helicobacter pylori Administer this medicine 20 mg with amoxicillin 1 g and clarithromycin 500 mg twice daily for 7 days. 3) Short-term treatment of upper gastrointestinal symptoms (pain, discomfort, heartburn) associated with nonsteroidal anti-inflammatory drug use (nonselective or selective COX-2 inhibitors) - 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is necessary. Clinical studies lasting more than 4 weeks have not been conducted. 4) Patients requiring continuous nonsteroidal anti-inflammatory drug treatment - Treatment of gastric ulcers associated with nonsteroidal anti-inflammatory drug use: 20 mg once daily. The treatment period is 4∼8 weeks. - Prevention of gastric and duodenal ulcers associated with nonsteroidal anti-inflammatory drug use: 20 mg once daily. 5) Treatment of Zollinger-Ellison syndrome The recommended initial dose is 40 mg twice daily. Subsequent doses should be adjusted for each patient, and treatment should continue while clinical symptoms are present. Clinical data indicate that most patients can be controlled with doses of 80 ∼ 160 mg per day. Doses greater than 80 mg per day should be divided into two doses. 6) Maintenance therapy following induction of prevention of rebleeding from gastric or duodenal ulcers by intravenous injection Administer 40 mg once daily for 4 weeks following induction of prevention of rebleeding from gastric or duodenal ulcers by intravenous injection. 4. Renal impairment No dose adjustment is necessary. Use with caution because there is limited experience with administration to patients with severe renal impairment. 5. Hepatic impairment No dose adjustment is necessary in patients with mild to moderate hepatic impairment. The dose of this medicine must not exceed 20 mg in patients with severe hepatic impairment. 6. Elderly patients No dose adjustment is necessary.

Children's dosage

Adolescents aged 12 years and older 1) Gastroesophageal reflux disease (GERD) - Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. For patients whose esophagitis has not healed or whose symptoms persist, continue treatment for an additional 4 weeks. - Symptomatic treatment of gastroesophageal reflux disease without esophagitis: · 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is necessary. · Once symptoms have resolved, subsequent recurrent symptoms may be controlled with 20 mg once daily. · In adults, 20 mg may be taken once daily as needed. As-needed use to control recurrent symptoms is not recommended for patients at high risk of gastric and duodenal ulcers due to nonsteroidal anti-inflammatory drug use. Children under 12 years There is no experience with administration of this medicine to children under 12 years.

Precautions

This medication should not be used in patients with a known hypersensitivity to any of its ingredients or to benzimidazoles in the past. In addition, when used in combination for the eradication of Helicobacter pylori with amoxicillin or clarithromycin, it should not be given to patients who are allergic to those antibiotics. Patients with certain heart diseases or a history of myocardial infarction, as well as nursing women, should also avoid using this medication. This medication contains the pigment Yellow No. 5; patients with allergy or hypersensitivity to this component should use it cautiously. Regular monitoring is necessary for long-term use, and patients should consult their physician if there are any changes in symptoms. Since this medication reduces gastric acid, it may slightly increase the risk of bacterial infections in the gastrointestinal tract; therefore, if diarrhea persists, patients should inform their healthcare provider. Additionally, long-term use may increase the risk of fractures, so patients at risk of osteoporosis should periodically check their bone health. This medication may interact with other drugs, particularly anticoagulants, antiviral drugs, and antibiotics; therefore, patients should strictly follow their healthcare provider's instructions when taking these together. Women who are pregnant or breastfeeding should discuss its use with their physician before use. In the case of an overdose, there is no specific antidote, so symptomatic treatment should be received and followed according to the healthcare provider's instructions. Finally, it should be kept in a secure place out of reach of children and should not be transferred to another container.

Side effects

Leukopenia, thrombocytopenia, agranulocytosis, pancytopenia, fever, angioedema, anaphylactic reaction, shock, peripheral edema, hyponatremia, hypomagnesemia, insomnia, anxiety, confusion, depression, aggression, hallucinations, headache, dizziness, paresthesia, drowsiness, taste disturbance, blurred vision, bronchospasm, pancreatitis, abdominal pain, constipation, diarrhea, abdominal distension, nausea, vomiting, dry mouth, stomatitis, gastrointestinal candidiasis, microscopic colitis, increased liver enzymes, jaundice, hepatitis, liver failure, encephalopathy, dermatitis, itching, rash, urticaria, hair loss, photosensitivity, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, acute generalized pustular psoriasis, drug reaction with eosinophilia and systemic symptoms, fractures, arthralgia, myalgia, muscle weakness, interstitial nephritis, gynecomastia, asthenia, increased sweating, Clostridium difficile-associated diarrhea, abdominal distention, allergic reaction, back pain, chest pain, sternal pain, facial edema, facial flushing, fatigue, fever, influenza-like illness, generalized edema, leg edema, malaise, pain, stiffness, peripheral edema, flushing, hypertension, tachycardia, thyroid enlargement, irritable bowel syndrome, exacerbation of constipation, dyspepsia, dysphagia, gastrointestinal malformation, epigastric pain, belching, esophageal disturbances, frequent bowel movements, gastroenteritis, gastrointestinal bleeding, hiccups, melena, oral disturbances, pharyngeal disturbances, rectal disturbances, gastrointestinal symptoms, increased serum gastrin, tongue disturbances, tongue swelling, ulcerative stomatitis, vomiting, earache, tinnitus, anemia, hypopigmented anemia, cervical lymphadenopathy, nosebleeds, leukocytosis, leukopenia, thrombocytopenia, hyperbilirubinemia, abnormal liver function, increased ALT, increased AST, diabetes, hyperuricemia, increased ALP, polydipsia, vitamin B12 deficiency, weight gain, weight loss, exacerbation of arthritis, arthropathy, seizures, fibromyalgia syndrome, hernia, polymyalgia rheumatica, arthralgia, anorexia, apathy, increased appetite, confusion, worsening depression, hypertonia, anxiety, sensory loss, erectile dysfunction, insomnia, migraine, exacerbation of migraine, sleep disorders, tremors, dizziness, visual field defects, paresthesia, drowsiness, dysmenorrhea, menstrual disorders, vaginitis, exacerbation of asthma, cough, dyspnea, laryngeal edema, pharyngitis, rhinitis, sinusitis, acne, anal itching, rash, erythematous rash, papular rash, angioedema, dermatitis, itching, urticaria, increased sweating, otitis media, dysosmia, ageusia, gustatory hallucination, urinary abnormalities, albuminuria, cystitis, dysuria, fungal infections, hematuria, urinary frequency, candidiasis, genital candidiasis, polyuria, conjunctivitis, visual disturbances, duodenitis, esophagitis, esophageal stricture, esophageal ulcer, esophageal varices, gastric ulcer, gastritis, benign polyps or nodules, Barrett's esophagus, mucosal discoloration, hernia, systemic lupus erythematosus, discoid lupus erythematosus, gastric fundic polyps, hypocalcemia, hypokalemia, rhabdomyolysis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to protect it from air and moisture. It is preferable to maintain the storage temperature between 1 and 30 degrees Celsius at room temperature to effectively preserve its efficacy and safety.

Appearance and packaging

Appearance

Pale pink round film-coated tablet

Package unit

28 tablets/box [14 tablets/PTP x 2]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.